WNTs and their downstream effectors regulate proliferation, death, and migration and cell fate decision. Deregulation of WNT signaling is associated with various cancers including GBM, which is the most malignant primary brain cancer. In this review, we will summarize the experimental evidence supporting oncogenic roles of WNT signaling in GBM and discuss current progress in the targeting of WNT signaling as an anti-cancer approach. In particular, we will focus on (1) genetic and epigenetic alterations that lead to aberrant WNT pathway activation in GBM, (2) WNT-mediated control of GBM stem cell maintenance and invasion, and (3) cross-talk between WNT and other signaling pathways in GBM. We will then review the discovery of agents that can inhibit WNT signaling in preclinical models and the current status of human clinical trials.
, Sun Hee Ahn 1 , Jeongwu Lee 3 and Do-Hyun Nam 1, 4 WNTs and their downstream effectors regulate proliferation, death, and migration and cell fate decision. Deregulation of WNT signaling is associated with various cancers including GBM, which is the most malignant primary brain cancer. In this review, we will summarize the experimental evidence supporting oncogenic roles of WNT signaling in GBM and discuss current progress in the targeting of WNT signaling as an anti-cancer approach. In particular, we will focus on (1) genetic and epigenetic alterations that lead to aberrant WNT pathway activation in GBM, (2) WNT-mediated control of GBM stem cell maintenance and invasion, and (3) cross-talk between WNT and other signaling pathways in GBM. We will then review the discovery of agents that can inhibit WNT signaling in preclinical models and the current status of human clinical trials. WNT signaling has crucial roles in controlling self-renewal and differentiation during central nervous system (CNS) development. Neural stem cells (NSCs) are a central component of the CNS, and are located in the fetal ventricular zone, the postnatal subventricular zone, and the hippocampus. WNT signaling is required for the development of NSCs. 1, 2 Aberrant activation of WNT signaling in NSCs leads to malignant transformation and development of brain tumors. 1, 3, 4 For example, WNT3A was demonstrated to upregulate WNT signaling activity and increase the clonogenic potential of NSCs. 1 In addition, constitutive activation of β-catenin increased the proliferation of mouse neural progenitor cells in vivo, whereas deletion of β-catenin decreased their proliferation. 5, 6 Collectively, these studies indicate roles for WNT signaling in NSC self-renewal and proliferation. Glioblastoma (GBM) has been designated by the World Health Organization as a grade IV cancer, and is the most common and lethal CNS tumor in adults. 7, 8 Currently, the standard-of-care treatment for GBM patients consists of maximal surgical resection followed by concurrent irradiation and chemotherapy. 9 Temozolomide (Temodal), a DNA alkylating agent, is the most commonly used chemotherapeutic agent. Despite these therapies, most patients eventually relapse. There is therefore an urgent clinical need for the development of effective anti-GBM therapeutics.
The prognosis for GBM patients is uniformly poor. GBM tumors harbor a profound degree of heterogeneity; inter-and intra-tumoral heterogeneity of GBM can be attributed to genomic and molecular diversity of tumors, as well as cellular hierarchy. Recent large-scale genomic studies have provided comprehensive genetic and molecular profiles of GBM. 8, 10, 11 Prominent genomic alterations frequently found in GBM include loss-of-function of tumor suppressors in the p53, phosphatase and tensin homolog and neurofibromatosis 1, and hyperactivation of receptor tyrosine kinase (RTK) signaling, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor, and the receptor for hepatocyte growth factor (MET). 8, [10] [11] [12] In addition, molecular subtypes of GBM have been identified, largely based on the expression profiling analyses of GBM specimens. The most robust GBM subtypes that have consistently been identified in multiple studies are the proneural and mesenchymal subtypes. 10, [13] [14] [15] On the other hand, GBM also appears to have a cellular hierarchy, whereby there exists a subpopulation of GBM cells that are enriched with the capacity for tumor initiation and propagation, and these cells drive tumor growth and treatment resistance. [16] [17] [18] [19] A large number of studies have suggested that WNT signaling is aberrantly activated in GBM and that it promotes GBM growth and invasion via the maintenance of stem cell properties. [20] [21] [22] [23] Here, we will review recent studies from the literature that have described the functions of WNT/β-catenin signaling in development and cancer, with particular emphasis on [24] [25] [26] [27] [28] [29] genetic and epigenetic alterations that lead to aberrant WNT pathway activation in GBM. We will then discuss the development of therapeutic approaches based on the inhibition of WNT activation and the current status of clinical trials based on agents targeting the WNT pathway.
OVERVIEW OF WNT SIGNALING
WNT proteins are a family of highly conserved secreted signaling molecules. Since the discovery of WNT signaling as an oncogene in mouse breast cancer models in 1982, 30 WNT signaling has emerged as a critical regulator of cell-cell interactions, cell fate decision, and migration. Mutations in WNT pathway components lead to specific developmental defects, whereas aberrant WNT signaling often leads to cancer. WNT proteins bind to receptors of the frizzled (FZD) and low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) families on the cell surface. Through several cytoplasmic components, the signal is transduced to β-catenin, which enters the nucleus and forms a complex with T-cell factor (TCF) to activate transcription of WNT target genes (canonical pathways). Non-canonical WNT pathways are β-catenin-independent, and are most often linked with the establishment of polarity and cytoskeleton-mediated processes. A simple diagrammatic overview of WNT signaling is shown in Figure 1 .
Canonical WNT Signaling
The canonical WNT signaling cascade is a key regulator in embryonic and adult stem cells. This signaling is initiated by the binding of WNT ligands to cysteine-rich domains of the FZD and LRP families on the cell surface. Activation of these receptors leads to disassembly of the complex consisting of AXIN, adenomatous polyposis coli (APC), and GSK3β, thereby stabilizing β-catenin. As a result, β-catenin is translocated from the cytoplasm into the nucleus where it forms a complex with T-cell factor/lymphoid enhancer factor (TCF/LEF) and promotes transcription of multiple target genes including c-MYC and cyclin D1. 31, 32 A recent report showed that FoxM1 promotes nuclear translocation and stabilization of β-catenin in GBM, via binding to cytoplasmic β-catenin, suggesting that FoxM1 can activate canonical WNT signaling in a ligand-independent manner. 33 Non-Canonical WNT Pathway Non-canonical WNT signaling, currently defined as the β-catenin-independent pathway, mainly affects cell polarity and WNT-Ca 2+ pathways. [34] [35] [36] These pathways have been reported to contribute to developmental processes including planar cell polarity in Drosophila, convergent extension movements during gastrulation, and cell migration of neuronal and epithelial origin. 34 -dependent serine/threonine phosphatase), leading to accumulation of nuclear factor of activated T cells in the nucleus. 39, 40 GENETIC/EPIGENETIC ALTERATIONS OF WNT SIGNALING COMPONENTS As mentioned above, aberrant WNT pathway activation is found in various type of cancer including GBM. Mutations in WNT signaling components (APC, β-catenin, AXIN, WTX, TCF4) can be the cause of WNT pathway activation in these tumors. [41] [42] [43] [44] [45] In colorectal cancer, mutations in WNT signaling components have been extensively characterized. Approximately 85% of colorectal tumors have mutations in APC, whereas an activating mutation in β-catenin was observed in 50% of colorectal tumors lacking APC mutations. [46] [47] [48] APC is a negative regulator of WNT pathway activation. Accordingly, most APC mutations are loss-offunction mutations. Similar to colon cancer, mutations in WNT signaling components (β-catenin, APC, and AXIN1) have been identified in medulloblastoma (a brain tumor primarily originating in the cerebellum). [49] [50] [51] [52] [53] Recent largescale genomic studies showed that β-catenin mutations in exon 3, corresponding to its phosphorylation site were found in 18-22% of medulloblastoma cases. 51, 52 An additional 5% had mutations in APC or AXIN1. 52, 53 β-Catenin mutations detected in hepatocellular carcinoma and medulloblastoma led to the disruption of phosphorylation and degradation of β-catenin, resulting in hyperactivation of WNT signaling. 43, 44, 54 Thus, the mutation status of the above WNT signaling components is an indicator of WNT activation in tumor.
In sharp contrast to colon cancer and medulloblastoma, no genomic mutations have been found in β-catenin and APC in GBM. 55, 56 Recently, Morris et al identified a homozygous deletion of FAT Atypical Cadherin 1 (FAT1), a negative effector of WNT signaling, in GBM. Copy number loss of FAT1 was found in nearly 20% of GBMs; WNT signalingassociated genes were enriched in this subset of GBMs, suggesting that FAT1 loss is a critical molecular event for WNT activation in GBM. The frequency of FAT1-inactivating mutations in GBM is about 1%, according to TCGA data set analysis.
Epigenetic silencing of negative effectors of WNT pathways can activate WNT signaling and contribute to malignant behavior in GBM. Soluble Frizzled-related proteins (FRPs) are soluble proteins that bind to WNT and interfere with WNT signaling. Dickkopf (DKK) acts as an antagonist of WNT signaling via binding to its co-receptor LRP. 57 Indeed, epigenetic silencing of WNT pathway inhibitor genes frequently occurs in gliomas, including promoter hypermethylation of sFRPs (sFRP1, sFRP2, sFRP4, sFRP5), Dickkopf (DKK1, DKK3) and Naked (NKD1, NKD2). In GBM, promoter hypermethylation of sFRP1, sFRP2 and NKD2 occurred in more than 40% of primary GBM specimens. 58 Roth et al reported the role of sFRP in the proliferation and migration of glioma cells. 58 In this study, ectopic expression of sFRP reduced glioma cell motility by decreasing MMP2. DKK1 promoter hypermethylation was identified in 50% of secondary GBM. 59, 60 Collectively, these studies indicate that epigenetic alterations but not genomic mutations of WNT signaling components have major roles in WNT activation in GBM.
WNT SIGNALING IN GBM STEMNESS WNT Signaling in Stem Cells
It is well-established that WNT signaling regulates stemness and stem cell niches in normal cells. 61, 62 For instance, intestinal stem cells harboring a TCF4 mutation could not sustain self-renewal of stem cells, resulting in the regression of intestinal tissues. 61 In the hair follicle system, ectopic expression of DKK caused a deficit of hair follicles and mammary gland, indicating the role of WNT signaling in stem cell niches. 62 In contrast, activation of WNT signaling by forced expression of a mutant β-catenin increased stem cell pools in the hair follicle. 63 The cancer stem cells (CSCs) model posits a cellular hierarchy, in which CSCs mainly drive tumor initiation and propagation. Some tumors may not follow the CSC model and there are ongoing controversies regarding the CSC immuno-phenotype, the reversibility of the stem cell state, and cell-of-origin. 17, 64 Characteristics that are often associated with CSCs include the capacity for self-renewal, similarity with normal stem cells, and tumorigenicity in vitro/vivo. 65 Several studies have shown that inhibition of WNT signaling via modulation of β-catenin, LEF and TCF impeded the clonogenic growth of various cancer cells. [66] [67] [68] [69] [70] In addition, WNT inhibitory factor 1 (WIF1) induced cellular senescence, thereby impeding stemness and tumor growth. 67 As two recent papers have provided excellent reviews of WNT signaling and CSCs, 71, 72 this review focuses on studies conducted in GBM.
WNT Signaling in GBM Stem Cells (GSCs)
Despite controversies in some tumor models, numerous studies support the theory that GSCs are the critical cell population that contributes to GBM malignancy, therapeutic resistance to standard therapies, and recurrence 18, 73, 74 ( Figure 2 ). Regulatory connections between WNT signaling and GSCs have been elucidated in the following studies. A study from Depinho group found that PLAGL2 on chromosome 20q11.21 is amplified in primary GBM specimens and GBM cell lines. 75 PLAGL2 maintained the self-renewal ability of GBM cells, while restraining NSC differentiation. Overexpression of PLAGL2 in astrocytes and GBM cells led to upregulation of WNT signaling components, including WNT6, FZD9, and FZD2. Thus, PLAGL2 appears to be important for stem cell maintenance and gliomagenesis via activation of canonical WNT signaling. 75, 76 Another recent report showed the involvement of WNT signaling in GSCs via FoxM1. 33 In this study, the authors showed that FoxM1 promotes β-catenin nuclear translocation by directly binding to β-catenin. Accordingly, the expression level of nuclear FoxM1 correlated with that of nuclear β-catenin in GBM patient specimens. High levels of FoxM1 in GSCs have also been reported elsewhere, in which FoxM1 was shown to be phosphorylated by MELK, a GSC-enriched kinase, and to promote self-renewal and chemo-resistance of GBM cells. 77 In addition, FoxM1 appears to selectively bind to the promoter of Sox2, a master regulator of GSC self-renewal, and promotes stem cell transcription programs in GSCs. 78 Rheinbay et al performed a comparative analysis of chromatin state in GSCs compared with the entire tumor and identified a set of developmental transcription factors unique to GSCs. They found that a human achaete-scute homolog (ASCL1) activates WNT signaling in GSCs by repressing the negative regulator DKK1. 79 Given that aberrant WNT activation in GBM is mediated by epigenetic regulation rather than genetic mutations, genome-wide epigenetic profiles will likely yield more insights in stem cell controlled mechanisms including the WNT pathway in GSCs. In addition, Bartscherer et al found that a conserved sevenpass transmembrane protein, Evi, is involved in the secretion of WNT ligands in Drosophila and human cells, affecting both canonical and non-canonical WNT signaling pathways. [80] [81] [82] Moreover, they showed that Evi was strongly expressed in gliomas and that Evi depletion in glioma cell lines impeded cellular proliferation, clonogenic growth, and invasion. 81 Other studies have shown that WNT signaling components such as Frizzled and Dishevelled 2 (Dvl2) are overexpressed in GBM, and that these genes promoted clonogenic growth and stem-like characteristics of GBM cells. 3, 68 Although most studies have addressed canonical WNT signaling, several studies have indicated the involvement of both canonical and non-canonical WNT signaling. 22, 83 WNT SIGNALING IN GBM INVASION Tumor metastasis is a major factor contributing to tumorassociated death. Epithelial-mesenchymal transition (EMT) is a critical process that enables cancer cells of epithelial origin to metastasize to distal organs. Unsurprisingly, WNT signaling is involved in both tumor invasion and EMT. Several studies have shown that WNT signaling activation enhances the motility of bladder, breast, and pancreatic cancer cells. [84] [85] [86] [87] Overexpression of positive WNT signaling regulators was found to increase the expression of EMT-associated genes, such as ZEB1, SNAIL, TWIST, SLUG, and N-cadherin, indicating the role of WNT in EMT [88] [89] [90] [91] [92] [93] [94] ( Figure 2 ). For example, ectopic expression of a constitutively active β-catenin induced the expression of ZEB1 in GBM cells and increased cell motility. 14 Conversely, inhibition of β-catenin suppressed cellular invasion in U87MG and LN229 GBM cells. 95 In addition, WNT5A was shown to induce migration in GBM cells by activating a β-catenin-independent pathway. WNT5A knockdown in glioma cells significantly inhibited the migratory capacity of these cells without affecting proliferation kinetics. 96 Consistent with this, expression of a recombinant WNT5A protein stimulated migration in GBM cells via increase of MMP2 activity. 96 Similar observations have been made using other WNT regulators such as WNT2 and FZD2. 96, 97 In comparison with other solid tumors, GBM rarely metastasizes to other. However, GBM tumor cells disseminate widely into the neighboring brain parenchyma. The invasive and infiltrative growth pattern of GBM makes it almost impossible to perform radical, maximal tumor resection. The involvement of WNT signaling activation in GBM invasiveness was shown in a recent report. 68 In this study, the authors enriched highly invasive GBM cell populations through serial in vivo transplantation assays and analyzed mRNA expression profiles of these populations. FZD4, a positive WNT regulator, was identified and shown to be a causative effector for invasive phenotypes of GBM cells. 68 Together, these findings collectively indicate that WNT signaling has critical roles in GBM invasion and provide a rationale for targeting WNT signaling as a potentially effective anti-GBM therapeutic approach.
WNT SIGNALING IN THERAPEUTIC RESISTANCE
Most cancers develop resistance to radiotherapy and chemotherapy. Several studies have suggested that the activation of WNT signaling induces drug resistance in various cancers, including ovarian, colon and pancreatic cancer [98] [99] [100] ( Figure 2 ). For example, WNT5A was upregulated in oxaliplatin-resistant ovarian carcinoma cell line. 98 Ectopic expression of WNT5A conferred greater resistance of ovarian cancer cells to paclitaxel, 5-fluorouracil, epirubicin, and etoposide. 100 WNT5A activated Akt signaling and rendered colon cells resistant to histone deacetylase inhibitors. 101 Conversely, inhibition of WNT5A led to increased druginduced apoptosis in pancreatic cancer. 102 In GBM, Auger et al reported that WNT signaling promotes resistance to temozolomide, a standard chemotherapeutic agent for GBM patients. Activation of WNT signaling components such as FZD2 was also demonstrated in temozolomide-resistant subclones. 103 WNT signaling also contributes to radioresistance of cancer cells. [104] [105] [106] In breast cell models, stabilized β-catenin selectively reinforced mammosphere formation and enhanced radioresistance in the Sca1 + subpopulation compared with the corresponding Sca1 − cells. 105, 106 TCF4 was also shown to be required for radioresistance of colorectal cancer cell lines. 107 In GBM, Bao et al showed that CD133 + GSC-enriched cells were more resistant to irradiation than CD133 − cells; that was due in part to the enhanced DNA repair capacities of CD133 + cells. 108 These results imply that CD133 + tumor cell population confers radioresistance to GBM and most likely contributes to GBM recurrence. Similarly, Zheng et al showed that FoxM1 promotes GBM resistance via upregulation of Rad51, a critical component of the DNA damage repair process. 109 Using in vivo orthotopic xenograft tumor models combined with in vivo irradiation, Kim et al have obtained gene signatures that are highly enriched in radioresistant GBM cells compared with the parental tumor cells. 110 Radioresistant GBM cells expressed high levels of WNT signaling-related genes, such as WISP1, FZD1, LEF1, TCF4, WNT9B, and AXIN2. Inhibition of the WNT pathway by XAV939, a WNT signaling inhibitor, sensitized GBM cells to irradiation.
CROSS-TALK BETWEEN WNT AND OTHER SIGNALING PATHWAYS IN GBM
RTKs promote GBM survival, proliferation, and invasion. Hyperactivation of RTK signaling because of genomic amplification and/or activating mutations of RTKs occurs in more than 90% of GBMs. 13, 111 Amplifications or somatic mutations in EGFR, platelet-derived growth factor receptor, FGFR, and MET often correlate with GBM subtypes. 13 In this section, we will address the potential relationships between WNT signaling and these RTK signaling pathways (Figure 3 ).
Cross-talk with EGFR Signaling Pathway EGFR amplification and hyperactivation were observed in 60% of GBM patients. [112] [113] [114] [115] Several activating mutations, most notably the EGFRvIII mutation, were also observed in GBM and are known to contribute to cancer development. Activation of EGFR induces downstream mitogenic signaling, such as the mitogen-activated protein kinase, phosphatidylinositol 3-kinase/Akt, and transducers and activators of transcription (STAT) pathways. 115, 116 Bioinformatic analysis with Search Tool for Retrieval of Interacting Genes/Proteins (STRING) indicated that β-catenin is associated with several genes, including Akt1, CCND1, JUN, tumor suppressors in the p53, and VEGFA. 95 Moreover, multiple signaling pathways, including the mitogen-activated protein kinase, insulin, focal adhesion and adherens junction and ErbB pathways, were proposed as β-catenin-related pathways. Based on these analyses, several studies attempted to find a relationship between the EGFR and WNT pathways. One study showed that β-catenin inhibition in GBM cell lines (U87MG and LN229) led to downregulation of EGFR, STAT3, Akt1, MMP2 and MMP9, FRA-1, and c-MYC. In another study, TCF4 downregulation reduced Akt1 expression by binding to the Akt1 promoter, indicating a link between AKT signaling and the WNT pathway. 117 Several reports have indicated that EGF signaling is an upstream regulator of the WNT pathway. 118,119 EGF-induced ERK2 upregulation resulted in phosphorylation of CK2a, and then CK2α with, and subsequent phosphorylation of, α-catenin at S641. 118 CK2α-mediated phosphorylation of α-catenin released α-catenin from binding to β-catenin, which led to shuttling of the latter into the nucleus where it formed a β-catenin/TCF/LEF complex. In addition, chronic EGF treatment resulted in downregulation of transcription of caveolin-1 and E-cadherin. 119 Loss of caveolin-1 induced β-catenin transactivation, whereas depletion of E-cadherin prevented cell-cell connection and induced EMT.
Cross-talk with MET Signaling Pathway
Hepatocyte growth factor receptor (MET) has crucial roles in cancer growth, stem cell maintenance, and metastasis. 120, 121 In GBM, expression levels of MET correspond with poor patient survival and malignancy. 8, 122 In addition, analyses of clinical GBM specimens revealed a positive association between MET expression and invasiveness-related genes (MMP2 and MMP9) and proto-oncogenes (c-MYC, KRAS, and JUN). 8 Several lines of evidence suggest that the MET signaling pathway is connected to WNT signaling in cancer, although this cross-talk in GBM is not been yet fully understood. Kim et al showed that activation of MET signaling by the addition of HGF-induced nuclear translocation of β-catenin. Moreover, MET inhibition by small molecules led to blockade of β-catenin nuclear translocation and TCF/LEF promoter activity, 123 suggesting the possibility that MET signaling is an upstream regulator of WNT signaling.
Cross-talk with Sonic Hedgehog (SHH) Signaling Pathway SHH signaling is a key pathway for cellular proliferation and tumorigenesis. [124] [125] [126] Molecular classification studies on medulloblastoma revealed that SHH and WNT are prominent signaling pathways that drive the formation of distinct tumor subgroups. 127, 128 GLI1 in medulloblastoma cells physically interacted with β-catenin and led to its degradation, supporting the possibility that SHH and WNT may not be co-activated in these tumors. 129 Indeed, mutations in SHH signaling components (eg, PTCH1 and SUFU), which led to aberrant SHH signaling activation, were found in 30% of medulloblastoma patients. 130 Although alterations of SHH signaling components and amplification of chromosome 12q region that contains GLI1 were rarely founded in gliomas, [131] [132] [133] [134] [135] activation of SHH pathways in GBM has been reported. For instance, blockade of SHH signaling with the chemical inhibitor Vismodegib induced cell cycle arrest and apoptosis, and downregulated GLI1 expression in patient-derived GBM cells. 136 Several studies have suggested that SHH signaling has a suppressive effect on WNT signaling. 129, 137, 138 For example, it was reported that GLI1 binds to the sFRP1 promoter and increases Figure 3 Cross-talk with other signaling pathways. Cross-talk with EGFR and MET signaling pathways are as follows. Ligand-mediated EGFR activation leads to CK2α phosphorylation, resulting in disassembly of α-catenin/β-catenin complex. (Left) Although the detailed mechanism is not precisely understood, it is known that MET activation increases the stability of β-catenin. The free cytoplasmic β-catenin is stabilized and translocates into the nucleus. Nuclear β-catenin binds to TCF/LEF transcription factor, which induces the expression of WNT signaling-target genes.
sFRP1 mRNA expression in GBM. Further studies are warranted to decipher the cross-talk between SHH signaling and WNT signaling in GBM.
TARGETING THE WNT SIGNALING PATHWAY IN GBM
Expression levels of WNT pathway genes have been found by multiple research groups to be associated with a poor prognosis in glioma patients. Through RT-PCR and immunohistochemical staining, expression levels of WNT components were analyzed. 31 mRNA expression of β-catenin, Dvl3, and cyclin D1 were significantly higher in glioma specimens compared with non-tumor brain tissue. Moreover, protein levels of β-catenin, TCF4, LEF1, c-MYC, n-MYC, c-JUN, and cyclin D1 were correlated positively with the degree of glioma. Among these components, β-catenin had a significantly positive correlation with TCF4 and LEF1. In a different study, expression of WNT1, β-catenin, and cyclin D1 was associated with malignancy and clinical outcomes of GBM patients. 32 Recent genomic studies have identified genetic and molecular heterogeneity between tumors and within GBM tumors. LEF1, a key effector of WNT signaling, appeared to regulate intra-tumoral heterogeneity, indicating a widespread interplay between this WNT signaling-related transcription factor and GBM driver pathways. 79,139 Figure 4 The multiple roles of WNT signaling in GBM. WNT signaling is one of the key signaling pathways in GBM. No genetic alterations of WNT signaling components were identified, whereas hypermethylation of WNT signaling repressors is observed in about 40-50% of GBM patients. WNT signaling has multiple roles during CNS development and gliomagenesis. The roles of WNT signaling are as follows: (1) stemness maintenance, (2) migration and invasion, and (3) induction of therapeutic resistance. Thus, therapeutic approaches that target WNT signaling will be important for eradication of GSCs and overcoming the resistance to standard therapies. Gene expressions by regulating EMT, stemness and WNT-related genes are altered as follows.
The above studies collectively indicate that WNT targeting can be an effective therapeutic approach against GBM (Table 1) . WNT signaling inhibitors have been identified and demonstrated therapeutic efficacy in various human cancers. [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] However, relatively little is known about clinically applicable WNT inhibitors for the treatment of GBM. In this section, we introduce a list of WNT signaling inhibitors that can be potentially used for anti-GBM therapy. Several drugs targeting WNT signaling have been or are being developed for clinical trials. These drugs can be largely classified into three groups: (1) non-steroidal anti-inflammatory drugs, (2) small-molecule chemical inhibitors, and (3) therapeutic antibodies that target various WNT pathway components (Figure 4) .
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used to treat treating inflammation, pain, and fever. NSAIDs inhibit the activity of the prostaglandin biosynthetic enzymes, the cyclooxygenase isoforms (COX-1 and COX-2). However, NSAIDs have shown anti-cancer effects as well as anti-inflammatory effects, and cross the blood-brain barrier efficiently. 150, 151 Therefore, NSAIDs have attracted much attention as potential anti-cancer agents. (Table 2 ) Aspirin is a fat-soluble small molecule that is used to relieve pain. Several studies have proposed that aspirin inhibits the 153 It has been confirmed that daily aspirin treatment for 5 years or longer reduces the risk of colon cancer. [154] [155] [156] In GBM, aspirin inhibited proliferation and invasiveness and increased apoptosis via G0/G1 arrest in U87MG and A172 cells. These effects were driven by downregulation of WNT signaling. Following treatment with aspirin, TCF/LEF promoter activity and expression of WNT signaling-target genes (c-MYC, Cyclin D1, and FRA-1) were decreased in GBM cell lines. 157 Diclofenac is one of the traditional NSAIDs and functions through inhibition of COX-1 and COX-2, whereas Celecoxib is a newly generated drug and selectively inhibits COX-2 activity. Treatment with these drugs reduced proliferation, colony formation, and migration of glioma cells. 158 Recent chemical screening efforts have identified several small-molecule inhibitors and antibodies targeted at WNT signaling (Table 3) . 159 A random selection of 16 000 small molecules were used in the screening. SEN461 was selected as a potent WNT signaling inhibitor and validated the molecular mechanism of action. SEN416 prevented proteosomal degradation of AXIN. Through the stabilization of AXIN, cytoplasmic level of phosphorylated β-catenin were increased, accompanied by a loss of total β-catenin. Experimentally, SEN461 was largely responsible for growth inhibition by suppressing WNT signaling in GBM cells. XAV939 is an antagonist of Tankyrase (TRF-1, TNK) by inhibiting its interaction with AXIN and regulating its stability. TNK enzyme activity mediated AXIN ubiquitination and proteosomal degradation. XAV939 controlled WNT signaling by increasing AXIN stabilization. 160 Kim et al have shown that XAV939 potently inhibited WNT signaling in radioresistant-U373 GBM cells. 110 However, no clinical progress of SEN461 or XAV939 has been reported to date. Antibodies targeting WNT signaling are categorized as follows: anti-ligand antibodies that trap and neutralize WNT ligands (WNT1, 2, 5A, and sFRP2) 140, 141, [161] [162] [163] and anti-FZD antibodies (FZD5 and FZD10). 142, 164, 165 Most antibodies suppressed in vitro/in vivo proliferation and migration of lung, colorectal, gastric, and breast cancer cells. To increase the ability of therapeutic antibodies to penetrate the bloodbrain barrier, new approaches (ie, nanoparticle conjugation and antibody engineering) are under investigation in the realm of therapeutic antibody development. 166, 167 CLOSING REMARKS WNT signaling contributes to GBM pathology at multiple levels including tumor initiation, maintenance of stem cell status, invasion, and therapeutic resistance. Although GBMs do not harbor genetic alterations in WNT signaling components, aberrant activation of WNT signaling appears to be achieved mainly by epigenetic silencing of negative WNT regulators and overexpression of positive regulators. Although WNT pathways have proven difficult to target, recent progress has been made in generating multiple agents that can potently inhibit WNT activation in preclinical models. Accumulating further data to support the crucial roles of WNT in GBM may increase the feasibility of WNT inhibition as a therapeutic approach to treat GBM patients.
